Tech Company Financing Transactions
Ascenta Therapeutics Funding Round
Ascenta Therapeutics closed a $30 million Series B funding round on 11/5/2005. Backers included Domain Associates, Enterprise Partners Venture Capital and Scale Venture Partners.
Transaction Overview
Company Name
Announced On
11/5/2005
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Proceeds Purpose
This new round of financing for the Company will enable Ascenta to rapidly bring its lead compound, AT-101, into Phase I in early 2005 and through Proof-of-Clinical Concept in several Phase II studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 Lindenwood Dr. 405
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Ascenta Therapeutics, a clinical-stage biopharmaceutical company, focuses on the discovery and development of new medicines to treat cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mel Sorensen
Chief Financial Officer
Joel Sussman
VP - Bus. Development
Brian Wood
VP - Operations
Jeffrey Brill
Browse more venture capital transactions:
Prev: 11/4/2005: Yelp venture capital transaction
Next: 11/7/2005: Fovea Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs